Drugs / ING-1(heMAb)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00051675 | Jul 2002 → Sep 2003 | adenocarcinoma | XOMA (US) LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ING-1(heMAb) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00051675 ↗ |
| Modality | Monoclonal antibody | “Human-Engineered Monoclonal Antibody” NCT00051675 ↗ |
| Route | Subcutaneous | “Subcutaneously Administered Human-Engineered Monoclonal Antibody” NCT00051675 ↗ |